Alteration of cytochrome oxidase subunit I labeling is associated with severe mitochondriopathy in NRTI-related hepatotoxicity in HIV patients

Modern Pathology

Volumn 19, Issue 10, 2006, Pages 1277-1288

  Van Huyen, Jean Paul Duong ^a,b   Batisse, Dominique ^a   Heudes, Didier ^a,b   Belair, Marie France ^b   Piketty, Christophe ^a   Gonzalez Canali, Gustavo ^a   Weiss, Laurence ^a   Kazatchkine, Michel D ^a   Bruneval, Patrick ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Electron microscopy; Immunohistochemistry; Liver biopsy; Mitochondrial toxicity; Nucleoside reverse transcriptase inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; CELL NUCLEUS DNA; CYTOCHROME C OXIDASE; MITOCHONDRIAL DNA; PROTEIN SUBUNIT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CELL DAMAGE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON MICROSCOPY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULTRASTRUCTURE ANALYSIS AND ELECTRON MICROSCOPY;

ADULT; ELECTRON TRANSPORT COMPLEX IV; FATTY LIVER; FEMALE; HEPATITIS, TOXIC; HIV INFECTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; MITOCHONDRIA, LIVER; MITOCHONDRIAL DISEASES; PROTEIN SUBUNITS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33748863608     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800652     Document Type: Article

References (30)

1. Schreider MF, Gauge SJ, Williams CM, et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. Aids 2005;19:2009-2018.
2. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (MORTAVIC 2001 study). Aids 2003; 17:1803-1809.
3. Pol S, Vallet-Pichard A, Fontaine H. Hepatitis C and HIV co-infection at the era of HAART. J of Viral Hepatitis 2002;9:1-8.
4. Allory Y, Charlotte F, Benhamou Y, et al. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. The MULTIVIRC group. Hum Pathol 2000;31:69-74.
5. Rullier A, Trimoulet P, Neau D, et al. Fibrosis is worse in HIV-HCV patients with low-level immunodepression referred for HCV treatment than in HCV-matched patients. Hum Pathol 2004;35:1088-1094.
6. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity-a challenge for the hepatologist? J Hepatol 2002;36:283-294.
7. Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. Aids 2004;18: 137-151.
8. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003;2:812-822.
9. Ogedegbe AE, Thomas DL, Diehl AM. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis 2003;3:329-337.
10. Van Huyen JP, Landau A, Piketty C, et al. Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy. Am J Clin Pathol 2003;119:546-555.
11. Batisse D, Van Huyen JP, Piketty C, et al. Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues. Aids 2002;16:2370-2371.
12. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-820.
13. Reiss P, Casula M, de Ronde A, et al. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs single (zidovudine) nucleoside reverse transcriptase inhibitors. HIV Med 2004;5:11-14.
14. Lopez S, Miro O, Martinez E, et al. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir Ther 2004;9:47-55.
15. Chiappini F, Teicher E, Saffroy R, et al. Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients. Lab Invest 2004;84:908-914.
16. Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion. Hum Pathol 2001;32:734-740.
17. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24: 289-293.
18. Verucchi G, Calza L, Biagetti C, et al. Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2004;35:326-328.
19. Laguno M, Milinkovic A, de Luzzari E, et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther 2005;10: 423-429.
20. Bani-Sadr F, Carrat F, Pol S, et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 2005;40:47-52.
21. Miro O, Lopez S, Martinez E, et al. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 2004;39:710-716.
22. Miura T, Goto M, Hosoya N, et al. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol 2003;70:497-505.
23. Barbaro G, Di Lorenzo G, Asti A, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. Am J Gastroenterol 1999;94:2198-2205.
24. Rust C, Gores GJ. Does hepatitis C cause liver injury by pathways associated with mitochondrial dysfunction? Am J Gastroenterol 1999;94:2003-2005.
25. Pessayre D, Berson A, Fromenty B, et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001;21: 57-69.
26. Asselah T, Boyer N, Marcellin P. Steatosis in hepatitis C: What does it mean? Curr Hepat Rep 2003; 2:137-144.
27. de Mendoza C, Soriano V. The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV-HCV coinfected individuals. Antivir Ther 2005;10(supple 2):M109-M115.
28. Bauerle J, Laguno M, Mauss S, et al. Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: contributing effect of HIV infection? HIV Med 2005;6:135-139.
29. Vittecoq D, Jardel C, Barthelemy C, et al. Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder? J Acquir Immune Defic Syndr 2002;31:299-308.
30. Walker UA, Bauerle J, Laguno M, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004;39:311-317.